Venker Eric 4

4 · Immunovant, Inc. · Filed Apr 9, 2026

AI-generated summary of this filing

Updated Apr 9, 2026

Immunovant (IMVT) CEO Eric Venker Receives RSU and Option Grants

What Happened

Eric Venker, CEO of Immunovant (IMVT), received equity awards on April 7, 2026: 232,252 restricted stock units (RSUs) and 336,043 stock options. Both awards were granted at $0.00 (no cash paid at grant) as reported on Form 4 (transaction code A — award/grant).

Key Details

Transaction date: 2026-04-07; filing date: 2026-04-09 (filed timely).
RSUs: 232,252 units; each RSU converts to one share upon vesting. Vesting: 25% on April 1, 2027, then the remainder in 12 substantially equal quarterly installments (footnote F1); subject to continuous service.
Options: 336,043 options (derivative award); vesting: 25% on April 1, 2027, then the remainder in 36 substantially equal monthly installments (footnote F2); subject to continuous service.
Acquisition price shown: $0.00 for both grants.
Shares owned following the transaction: not specified in the information provided in this filing.

Context

RSUs are a contingent right to receive shares upon vesting; options are rights to purchase shares subject to vesting. These are standard equity compensation grants under the Issuer's 2019 Equity Incentive Plan and do not indicate a market sale or purchase by the insider.

Form 4

Period: 2026-04-07

DirectorChief Executive Officer

Transactions

Award
Common Stock
[F1]
2026-04-07+232,252→ 251,813 total
Award
Stock Option (right to buy)
[F2]
2026-04-07+336,043→ 336,043 total
Exercise: $24.61Exp: 2036-04-07→ Common Stock (336,043 underlying)

Footnotes (2)

[F1]These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.
[F2]These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Signature

/s/ Tiago Girao, Attorney-in-Fact for Eric Venker|2026-04-09

1 file